<DOC>
	<DOCNO>NCT00686348</DOCNO>
	<brief_summary>To assess safety effectiveness Somatuline® Depot ( lanreotide ) Injection administer health care professional ( HCP ) , patient , patient 's partner parent/guardian part routine acromegaly care .</brief_summary>
	<brief_title>Somatuline® Depot ( Lanreotide ) Acromegaly Post-Marketing Observational Study</brief_title>
	<detailed_description>The objective post-marketing observational study ass safety effectiveness , measure insulin-like growth factor-1 ( IGF-1 ) growth hormone ( GH ) level , Somatuline® Depot ( lanreotide ) Injection administer health care professional ( HCP ) , patient , patient 's partner parent/guardian part routine acromegaly care . Treatment convenience acromegaly symptom relief also assess questionnaire , demographic medical history information collect .</detailed_description>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<criteria>The patient must clinical diagnosis acromegaly The patient must treat Somatuline® Depot ( include patient newly prescribe Somatuline® Depot ) The patient legally authorize representative must able understand protocol give sign informed consent . Assent patient also obtain , appropriate . Signed informed consent assent must obtain studyrelated activity conduct . Symptomatic , untreated biliary lithiasis Known hypersensitivity somatostatin analog related compound ( e.g. , octreotide )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>acromegaly</keyword>
</DOC>